|
|
|
|
Science Sparks @ ACTREC
|
 11th July 2022 |
Vol. No. 11; Issue No. 534 |
|
|
Publications
|
|
1. Behel V,Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K (2022). Molecular tumor board–guided treatment of non–small cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Research, Statistics and Treatment. 5(2): 337-341.
2. Mahajan A, Agarwal U, Patil V, Patil V, Vaish R, Noronha V,D'Cruz A, Chaturvedi P, Ghosh Laskar S, Sable N, Janu A, Shukla S, Patil A, Menon M, Rane S, Mittal N, Joshi A, Menon N, Prabhash K (2022). Proposed sub- compartmentalisation of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and AJCC 8th edition. A narrative review. Cancer Research, Statistics Treatment. 5(2): 293-300.
3. Gattani S, Ramaswamy A, Noronha V, Castelino R, Kumar S, Rao A, Dhekle R, Krishnamurthy J, Kannan S, Gota V, Banavali S, Badwe R, Prabhash K (2022). ECOG performance status as a representative assessment of deficits in older Indian patients with cancer – A cross‑sectional analysis from a large cohort study. Cancer Research, Statistics and Treatment. 5(2): 280-286.
4. Moiyadi AV (2022). Neuropsychologists and their role in developing an awake craniotomy program. Neurology India. 70:1291-1292.
5. Behel V, Noronha V, Choughule A, Shetty O, Chandrani P, Kapoor A, Bondili SK, Bajpai J, Kumar R, Pai T, Bal M, Gurav M, Bapat P, Mittal N, Menon S, Patil V, Menon N, Dutt A, Prabhash K (2022). Impact of molecular tumor bard on the clinical management of patients With cancer. JCO Global Oncology.
6. Tibdewal A, Pathak R, Kumar A, Anand S, Ghosh Laskar S, Sarin R, Chopra S, Engineer R, Laskar S, Murthy V, Gupta T, Agarwal JP (2022). Impact of the first Wave of COVID-19 pandemic on radiotherapy practice at Tata Memorial Centre, Mumbai: A longitudinal cohort study. JCO Global Oncology.
Book Chapter
Kumar S, Gupta S, Maurya AP, Singh R, Nigam S. (2022). Hormonal and Targeted Treatments in Breast Cancer. In: Sharma, SC, Mazumdar, A, Kaushik R. (Eds.) Breast Cancer. Springer, Singapore. Pp. 443–463.
Thesis
Sarika Tilwani. 2022. The role of 14-3-3ε in regulating development of the epidermis. (HBNI No.: LIFE09201504016) (Guide: Dr. Sorab N Dalal)
|
|
|
|
|
Interesting Reads
|
|
Bal E, Kumar M, Hadigol M, Holmes Am Hilton L, Loh J, Dreval K, Wong J, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin R, Khiabanian L, Dalla- Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature, 2022.
|
|
|
Legends of Science
|
|
Nitya Anand
Nitya Anand earned his Ph.D. from the University Department of Chemical Technology, Mumbai in 1948. He received his second Ph.D. from St. John's College at Cambridge University in 1950. His important research was the demonstration of immunomodulators like MDP's role in controlling infectious diseases and enhancing the effect of chemotherapy. Discovering new drugs such as Centchroman, Centbutindole, a neuroleptic, and Centbucridine, a local anesthetic, were his significant contributions. Dr. Nitya Anand is a Fellow of the National Academy of Sciences, Allahabad; Indian Academy of Sciences, Bengaluru; and President of the Indian Pharmaceutical Congress. He was the recipient of the Padma Shri Award in 2012.
|
|
| |
|
Akhil Chandra Banerjea
Akhil Chandra Banerjea obtained his Ph.D. from the National Institute of Virology, Pune, in 1983. He worked on the effect of lentiviral vectors, stem cells, catalytic nucleic acids, and siRNA for developing gene therapy against HIV/AIDS and studying host or viral genes in understanding HIV/AIDS pathogenesis. He is an elected fellow of the National Academy of Sciences and the Indian National Science Academy. The DBT of the Government of India awarded him the National Bioscience Award for Career development in 2001. He is also elected fellow of the National Academy of Sciences, India, and the Indian National Science Academy.
|
|
| |
|
|
|
|
Do You Know?
In 2004, Azacitidine, an inhibitor of DNA methylation and a pioneering epigenetic therapy, became the first drug to gain US Food and Drug Administration (FDA) approval for the treatment of myelodysplastic syndrome.
|
|
|
|
Cancer News
|
|
|
| |
|
Algae-based microrobots fight cancer
|
|
07 July 2022, Science News
|
|
Biohybrid microrobots consist of both living and synthetic components. While the “living part” of the robot usually provides mobility and transport, scientists can add extra functionalities to carry out specific functions, such as the release of a drug inside the body to treat cancerous tissue...
|
|
|
| |
|
IIT Madras AI tool maps cancer-causing genes
|
|
07 July 2022, Indian Express
|
|
IIT Madras researchers have built AI prediction models for three different types of cancer, including breast Invasive carcinoma, colon adenocarcinoma and lung adenocarcinoma... |
|
|
| |
|
|
|
|
|
|
� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
